Loading…
Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging
Study Objective To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole. Design Single‐center, retrospective cohort study. Setting Large community teaching hospital. Patients A total of 568 adults who underwent sing...
Saved in:
| Published in: | Pharmacotherapy 2017-06, Vol.37 (6), p.657-661 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83 |
| container_end_page | 661 |
| container_issue | 6 |
| container_start_page | 657 |
| container_title | Pharmacotherapy |
| container_volume | 37 |
| creator | Amer, Kallie A. Hurren, Jeff R. Edwin, Stephanie B. Cohen, Gerald |
| description | Study Objective
To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole.
Design
Single‐center, retrospective cohort study.
Setting
Large community teaching hospital.
Patients
A total of 568 adults who underwent single‐photon emission tomography MPI with either regadenoson (284 patients) or dipyridamole (284 patients) as a vasodilator agent, following an institution conversion from regadenoson to dipyridamole in the MPI protocol on July 15, 2013, for cost‐saving purposes.
Measurements and Main Results
Data were collected from the patients’ electronic medical records. The primary endpoint was the composite occurrence of any documented adverse event in each group. Secondary endpoints were individual components of the primary endpoint, reason for termination of the MPI examination (protocol completion or premature end due to an adverse event), use of an interventional agent to an treat adverse event, and cost‐related outcomes. A higher proportion of patients in the regadenoson group experienced an adverse event than those who received dipyridamole (84.9% vs 56.7%, p |
| doi_str_mv | 10.1002/phar.1940 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1896037782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1896037782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83</originalsourceid><addsrcrecordid>eNp1kcFO3DAQhq2Kqiy0h74AssQFDgHbiWOb22oLBYmqK1TOlhNPFqPEDvYGlHsfvAlLe0DqaUYz33wa6UfoKyVnlBB23j-YeEZVQT6gBZWCZ4rSYg8tCBMiI4TIfXSQ0uOE0rJgn9A-k4XgjKsF-n0HG2PBhxQ8foaYhoS_uX6MzpoutHCBl3gVut5ENxOhwdsHwFcRngbw9TgPlna-A3z5DH6bsPN4bbbutb_3FuImOL_BP8ZQm2idafEaYjMkN-luOrOZlp_Rx8a0Cb681UN0f3X5a3Wd3f78frNa3mZ1znOSmaKqiAJLKs6hUsxSyRolORMFCEJrkDUvG6oEF1Vdcgq2AcuKXFDIy8LI_BCd7Lx9DNP_aas7l2poW-MhDElTqUqSCyHZhB6_Qx_DEP30naaKMiJyKWbh6Y6qY0gpQqP76DoTR02JnqPRczR6jmZij96MQ9WB_Uf-zWICznfAi2th_L9Jr6-Xd6_KP1d5mcE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912073878</pqid></control><display><type>article</type><title>Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging</title><source>Wiley</source><creator>Amer, Kallie A. ; Hurren, Jeff R. ; Edwin, Stephanie B. ; Cohen, Gerald</creator><creatorcontrib>Amer, Kallie A. ; Hurren, Jeff R. ; Edwin, Stephanie B. ; Cohen, Gerald</creatorcontrib><description>Study Objective
To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole.
Design
Single‐center, retrospective cohort study.
Setting
Large community teaching hospital.
Patients
A total of 568 adults who underwent single‐photon emission tomography MPI with either regadenoson (284 patients) or dipyridamole (284 patients) as a vasodilator agent, following an institution conversion from regadenoson to dipyridamole in the MPI protocol on July 15, 2013, for cost‐saving purposes.
Measurements and Main Results
Data were collected from the patients’ electronic medical records. The primary endpoint was the composite occurrence of any documented adverse event in each group. Secondary endpoints were individual components of the primary endpoint, reason for termination of the MPI examination (protocol completion or premature end due to an adverse event), use of an interventional agent to an treat adverse event, and cost‐related outcomes. A higher proportion of patients in the regadenoson group experienced an adverse event than those who received dipyridamole (84.9% vs 56.7%, p<0.0001). None of the patients in either group required early MPI study termination due to an adverse event. No significant differences were noted between groups regarding use of aminophylline or other interventions to treat adverse events. The overall drug cost savings in the postconversion dipyridamole group was $51,526.
Conclusion
Dipyridamole was associated with fewer adverse events than regadenoson in patients undergoing MPI. Dipyridamole offers a safe and cost‐effective alternative to regadenoson for cardiac imaging studies.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1002/phar.1940</identifier><identifier>PMID: 28475259</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adenosine A2 Receptor Agonists - adverse effects ; Adenosine A2 Receptor Agonists - economics ; Aged ; Aminophylline ; cardiac stress test ; Cohort Studies ; Cost control ; Cost-Benefit Analysis - methods ; Dipyridamole ; Dipyridamole - adverse effects ; Dipyridamole - economics ; Dyspnea - chemically induced ; Dyspnea - economics ; Electronic medical records ; Emission measurements ; Female ; Gastrointestinal Diseases - chemically induced ; Gastrointestinal Diseases - economics ; Heart diseases ; Heart Diseases - diagnostic imaging ; Heart Diseases - economics ; Humans ; Male ; Medical imaging ; Middle Aged ; myocardial perfusion imaging ; Myocardial Perfusion Imaging - adverse effects ; Myocardial Perfusion Imaging - economics ; Myocardial Perfusion Imaging - methods ; Perfusion ; Purines - adverse effects ; Purines - economics ; Pyrazoles - adverse effects ; Pyrazoles - economics ; regadenoson ; Retrospective Studies ; Vasodilator Agents - adverse effects ; Vasodilator Agents - economics</subject><ispartof>Pharmacotherapy, 2017-06, Vol.37 (6), p.657-661</ispartof><rights>2017 Pharmacotherapy Publications, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83</citedby><cites>FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28475259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amer, Kallie A.</creatorcontrib><creatorcontrib>Hurren, Jeff R.</creatorcontrib><creatorcontrib>Edwin, Stephanie B.</creatorcontrib><creatorcontrib>Cohen, Gerald</creatorcontrib><title>Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Study Objective
To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole.
Design
Single‐center, retrospective cohort study.
Setting
Large community teaching hospital.
Patients
A total of 568 adults who underwent single‐photon emission tomography MPI with either regadenoson (284 patients) or dipyridamole (284 patients) as a vasodilator agent, following an institution conversion from regadenoson to dipyridamole in the MPI protocol on July 15, 2013, for cost‐saving purposes.
Measurements and Main Results
Data were collected from the patients’ electronic medical records. The primary endpoint was the composite occurrence of any documented adverse event in each group. Secondary endpoints were individual components of the primary endpoint, reason for termination of the MPI examination (protocol completion or premature end due to an adverse event), use of an interventional agent to an treat adverse event, and cost‐related outcomes. A higher proportion of patients in the regadenoson group experienced an adverse event than those who received dipyridamole (84.9% vs 56.7%, p<0.0001). None of the patients in either group required early MPI study termination due to an adverse event. No significant differences were noted between groups regarding use of aminophylline or other interventions to treat adverse events. The overall drug cost savings in the postconversion dipyridamole group was $51,526.
Conclusion
Dipyridamole was associated with fewer adverse events than regadenoson in patients undergoing MPI. Dipyridamole offers a safe and cost‐effective alternative to regadenoson for cardiac imaging studies.</description><subject>Adenosine A2 Receptor Agonists - adverse effects</subject><subject>Adenosine A2 Receptor Agonists - economics</subject><subject>Aged</subject><subject>Aminophylline</subject><subject>cardiac stress test</subject><subject>Cohort Studies</subject><subject>Cost control</subject><subject>Cost-Benefit Analysis - methods</subject><subject>Dipyridamole</subject><subject>Dipyridamole - adverse effects</subject><subject>Dipyridamole - economics</subject><subject>Dyspnea - chemically induced</subject><subject>Dyspnea - economics</subject><subject>Electronic medical records</subject><subject>Emission measurements</subject><subject>Female</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Gastrointestinal Diseases - economics</subject><subject>Heart diseases</subject><subject>Heart Diseases - diagnostic imaging</subject><subject>Heart Diseases - economics</subject><subject>Humans</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Middle Aged</subject><subject>myocardial perfusion imaging</subject><subject>Myocardial Perfusion Imaging - adverse effects</subject><subject>Myocardial Perfusion Imaging - economics</subject><subject>Myocardial Perfusion Imaging - methods</subject><subject>Perfusion</subject><subject>Purines - adverse effects</subject><subject>Purines - economics</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - economics</subject><subject>regadenoson</subject><subject>Retrospective Studies</subject><subject>Vasodilator Agents - adverse effects</subject><subject>Vasodilator Agents - economics</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kcFO3DAQhq2Kqiy0h74AssQFDgHbiWOb22oLBYmqK1TOlhNPFqPEDvYGlHsfvAlLe0DqaUYz33wa6UfoKyVnlBB23j-YeEZVQT6gBZWCZ4rSYg8tCBMiI4TIfXSQ0uOE0rJgn9A-k4XgjKsF-n0HG2PBhxQ8foaYhoS_uX6MzpoutHCBl3gVut5ENxOhwdsHwFcRngbw9TgPlna-A3z5DH6bsPN4bbbutb_3FuImOL_BP8ZQm2idafEaYjMkN-luOrOZlp_Rx8a0Cb681UN0f3X5a3Wd3f78frNa3mZ1znOSmaKqiAJLKs6hUsxSyRolORMFCEJrkDUvG6oEF1Vdcgq2AcuKXFDIy8LI_BCd7Lx9DNP_aas7l2poW-MhDElTqUqSCyHZhB6_Qx_DEP30naaKMiJyKWbh6Y6qY0gpQqP76DoTR02JnqPRczR6jmZij96MQ9WB_Uf-zWICznfAi2th_L9Jr6-Xd6_KP1d5mcE</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Amer, Kallie A.</creator><creator>Hurren, Jeff R.</creator><creator>Edwin, Stephanie B.</creator><creator>Cohen, Gerald</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201706</creationdate><title>Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging</title><author>Amer, Kallie A. ; Hurren, Jeff R. ; Edwin, Stephanie B. ; Cohen, Gerald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenosine A2 Receptor Agonists - adverse effects</topic><topic>Adenosine A2 Receptor Agonists - economics</topic><topic>Aged</topic><topic>Aminophylline</topic><topic>cardiac stress test</topic><topic>Cohort Studies</topic><topic>Cost control</topic><topic>Cost-Benefit Analysis - methods</topic><topic>Dipyridamole</topic><topic>Dipyridamole - adverse effects</topic><topic>Dipyridamole - economics</topic><topic>Dyspnea - chemically induced</topic><topic>Dyspnea - economics</topic><topic>Electronic medical records</topic><topic>Emission measurements</topic><topic>Female</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Gastrointestinal Diseases - economics</topic><topic>Heart diseases</topic><topic>Heart Diseases - diagnostic imaging</topic><topic>Heart Diseases - economics</topic><topic>Humans</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Middle Aged</topic><topic>myocardial perfusion imaging</topic><topic>Myocardial Perfusion Imaging - adverse effects</topic><topic>Myocardial Perfusion Imaging - economics</topic><topic>Myocardial Perfusion Imaging - methods</topic><topic>Perfusion</topic><topic>Purines - adverse effects</topic><topic>Purines - economics</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - economics</topic><topic>regadenoson</topic><topic>Retrospective Studies</topic><topic>Vasodilator Agents - adverse effects</topic><topic>Vasodilator Agents - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amer, Kallie A.</creatorcontrib><creatorcontrib>Hurren, Jeff R.</creatorcontrib><creatorcontrib>Edwin, Stephanie B.</creatorcontrib><creatorcontrib>Cohen, Gerald</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amer, Kallie A.</au><au>Hurren, Jeff R.</au><au>Edwin, Stephanie B.</au><au>Cohen, Gerald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2017-06</date><risdate>2017</risdate><volume>37</volume><issue>6</issue><spage>657</spage><epage>661</epage><pages>657-661</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><abstract>Study Objective
To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole.
Design
Single‐center, retrospective cohort study.
Setting
Large community teaching hospital.
Patients
A total of 568 adults who underwent single‐photon emission tomography MPI with either regadenoson (284 patients) or dipyridamole (284 patients) as a vasodilator agent, following an institution conversion from regadenoson to dipyridamole in the MPI protocol on July 15, 2013, for cost‐saving purposes.
Measurements and Main Results
Data were collected from the patients’ electronic medical records. The primary endpoint was the composite occurrence of any documented adverse event in each group. Secondary endpoints were individual components of the primary endpoint, reason for termination of the MPI examination (protocol completion or premature end due to an adverse event), use of an interventional agent to an treat adverse event, and cost‐related outcomes. A higher proportion of patients in the regadenoson group experienced an adverse event than those who received dipyridamole (84.9% vs 56.7%, p<0.0001). None of the patients in either group required early MPI study termination due to an adverse event. No significant differences were noted between groups regarding use of aminophylline or other interventions to treat adverse events. The overall drug cost savings in the postconversion dipyridamole group was $51,526.
Conclusion
Dipyridamole was associated with fewer adverse events than regadenoson in patients undergoing MPI. Dipyridamole offers a safe and cost‐effective alternative to regadenoson for cardiac imaging studies.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28475259</pmid><doi>10.1002/phar.1940</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0008 |
| ispartof | Pharmacotherapy, 2017-06, Vol.37 (6), p.657-661 |
| issn | 0277-0008 1875-9114 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1896037782 |
| source | Wiley |
| subjects | Adenosine A2 Receptor Agonists - adverse effects Adenosine A2 Receptor Agonists - economics Aged Aminophylline cardiac stress test Cohort Studies Cost control Cost-Benefit Analysis - methods Dipyridamole Dipyridamole - adverse effects Dipyridamole - economics Dyspnea - chemically induced Dyspnea - economics Electronic medical records Emission measurements Female Gastrointestinal Diseases - chemically induced Gastrointestinal Diseases - economics Heart diseases Heart Diseases - diagnostic imaging Heart Diseases - economics Humans Male Medical imaging Middle Aged myocardial perfusion imaging Myocardial Perfusion Imaging - adverse effects Myocardial Perfusion Imaging - economics Myocardial Perfusion Imaging - methods Perfusion Purines - adverse effects Purines - economics Pyrazoles - adverse effects Pyrazoles - economics regadenoson Retrospective Studies Vasodilator Agents - adverse effects Vasodilator Agents - economics |
| title | Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A08%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regadenoson%20versus%20Dipyridamole:%20A%20Comparison%20of%20the%20Frequency%20of%20Adverse%20Events%20in%20Patients%20Undergoing%20Myocardial%20Perfusion%20Imaging&rft.jtitle=Pharmacotherapy&rft.au=Amer,%20Kallie%20A.&rft.date=2017-06&rft.volume=37&rft.issue=6&rft.spage=657&rft.epage=661&rft.pages=657-661&rft.issn=0277-0008&rft.eissn=1875-9114&rft_id=info:doi/10.1002/phar.1940&rft_dat=%3Cproquest_cross%3E1896037782%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3530-a4bb09ed0b55eb92d182f985274e701ce8c56f19757bc651edfed24371e364a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1912073878&rft_id=info:pmid/28475259&rfr_iscdi=true |